Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Turn Therapeutics Inc ( (TTRX) ) has issued an update.
On March 23, 2026, Turn Therapeutics Inc. entered into a secured growth capital loan facility of up to $25 million with Avenue Venture Opportunities Fund II, L.P., anchored by a $7 million tranche funded at closing and additional tranches tied to clinical and financing milestones. The debt, which matures in October 2029 and is secured against substantially all company assets including intellectual property, carries a minimum interest rate of 12.25%, features interest-only payments for at least 15 months, allows limited principal conversion into equity, and includes issuance of $1.2 million in common stock to the lender as part of the financing package.
Turn disclosed on March 24, 2026, that proceeds from the initial tranche are expected to extend its cash runway through the mid-year Phase 2 readout in moderate-to-severe atopic dermatitis and to support preparations for potential registrational trials of GX-03 in both atopic dermatitis and onychomycosis. Management indicated the full facility, if drawn, is expected to fund operations through the end of 2027, bolstering the company’s ability to advance its lead dermatology program while signaling lender confidence in its clinical progress and strengthening Turn’s position among emerging dermatology-focused biotechs.
The most recent analyst rating on (TTRX) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
Spark’s Take on TTRX Stock
According to Spark, TipRanks’ AI Analyst, TTRX is a Neutral.
Overall score is held down primarily by weak financial performance (no revenue, ongoing cash burn, and negative equity indicating financing risk). Technicals are a notable offset with bullish momentum (price above key moving averages and positive MACD). Valuation remains a headwind due to negative earnings and no dividend support.
To see Spark’s full report on TTRX stock, click here.
More about Turn Therapeutics Inc
Turn Therapeutics Inc. is a clinical-stage biotechnology and dermatology company focused on precision therapies for inflammatory skin diseases. Its lead candidate, GX-03, is a first-in-class, non-systemic topical treatment being developed for moderate-to-severe atopic dermatitis, with additional potential in onychomycosis and other dermatologic conditions.
The company targets patients with limited effective options in chronic inflammatory and infectious skin disorders. By advancing GX-03 across multiple indications, Turn aims to position itself as a differentiated player in the dermatology therapeutics market, addressing sizable unmet medical needs in eczema and nail fungus.
Turn’s pipeline strategy centers on leveraging GX-03’s topical profile to reduce systemic exposure and safety risks typically associated with systemic treatments. This approach underscores its effort to capture share in specialty dermatology, where payers and physicians are increasingly focused on efficacy, tolerability, and long-term disease control.
Average Trading Volume: 36,228
Technical Sentiment Signal: Strong Sell
Current Market Cap: $100.7M
See more data about TTRX stock on TipRanks’ Stock Analysis page.